share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  08/08 17:05

Moomoo AI 已提取核心信息

On August 8, 2024, Ginkgo Bioworks Holdings, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced a decrease in total revenue to $56 million, a 30% drop from the previous year, primarily due to a ramp down in K-12 testing in its Biosecurity segment. The Cell Engineering segment also saw a 20% revenue decline. The loss from operations increased to $(223) million, including stock-based compensation and restructuring costs. Ginkgo began a restructuring plan in May 2024, which included workforce reductions and facility consolidations, aiming to complete most actions in 2025. The estimated cost for the reduction in force is between $18.0 million to $22.0 million, primarily in the Cell Engineering segment. The company reaffirmed its 2024 total revenue outlook of $170-$190 million and is taking measures to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo's cash and cash equivalents balance stood at $730 million at the end of the second quarter.
On August 8, 2024, Ginkgo Bioworks Holdings, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced a decrease in total revenue to $56 million, a 30% drop from the previous year, primarily due to a ramp down in K-12 testing in its Biosecurity segment. The Cell Engineering segment also saw a 20% revenue decline. The loss from operations increased to $(223) million, including stock-based compensation and restructuring costs. Ginkgo began a restructuring plan in May 2024, which included workforce reductions and facility consolidations, aiming to complete most actions in 2025. The estimated cost for the reduction in force is between $18.0 million to $22.0 million, primarily in the Cell Engineering segment. The company reaffirmed its 2024 total revenue outlook of $170-$190 million and is taking measures to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo's cash and cash equivalents balance stood at $730 million at the end of the second quarter.
2024年8月8日,金戈生物科技控股公司公布了截至2024年6月30日第二季度的财务业绩。公司宣布,由于生物安全领域K-12测试的逐渐减少,总营业收入降至5600万美元,较上年下降了30%。电芯工程领域的收入也下降了20%。包括股票补偿和重组成本在内的营业亏损增加到了2.23亿美元。金戈于2024年5月开始了一项重组计划,其中包括减少员工和设施整合,旨在在2025年完成大多数行动。减员的预计成本在1800万美元到2200万美元之间,主要集中在电芯工程领域。公司重申了其2024年的总营业收入预期为1.7亿美元至1.9亿美元,并采取措施在2026年底前实现调整后的EBITDA盈亏平衡。截至第二季度末,金戈的现金及现金等价物余额为7.3亿美元。
2024年8月8日,金戈生物科技控股公司公布了截至2024年6月30日第二季度的财务业绩。公司宣布,由于生物安全领域K-12测试的逐渐减少,总营业收入降至5600万美元,较上年下降了30%。电芯工程领域的收入也下降了20%。包括股票补偿和重组成本在内的营业亏损增加到了2.23亿美元。金戈于2024年5月开始了一项重组计划,其中包括减少员工和设施整合,旨在在2025年完成大多数行动。减员的预计成本在1800万美元到2200万美元之间,主要集中在电芯工程领域。公司重申了其2024年的总营业收入预期为1.7亿美元至1.9亿美元,并采取措施在2026年底前实现调整后的EBITDA盈亏平衡。截至第二季度末,金戈的现金及现金等价物余额为7.3亿美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息